Together with pharmaceutical company Bayer, CureVac is working to make the first generation of the vaccine available as quickly and widely as possible. The European Union has now secured 225 million doses and an option for 180 million more, CureVac said. The vaccine is said to require a lower dosage of the active ingredient, which makes the vaccine more tolerable and also reduces production costs. In addition, CureVac's vaccine should be able to be stored at normal refrigerator temperatures. The Tübingen-based company expects to be able to produce 300 million doses of its CnCov vaccine by the end of the year and even up to one billion doses in 2022. CureVac already has a concrete plan for how to achieve rapid production of the CureVac vaccine. The Tübingen-based company is relying primarily on a large number of partners throughout Europe. Co. wants to start production as early as this month at a plant in Amsterdam - about 100 million doses are to be produced this year, and 200 million next year, according to Manager Magazin. Similar plans are being pursued by the Belgian "Wavre" plant of "Glaxosmithkline". In addition, the Corona vaccine is to be filled by the Luxembourg contract manufacturer "Valneva" in two French plants from the end of May or beginning of June, according to the Paris Ministry of Economy.<--Smart strategy might catapult them ahead of the others. "Novartis" is providing a plant in Austria for up to 50 million doses this year and 200 million next year. Swabian producer Rentschler Biopharma, announced in February it could supply up to 100 million vaccine doses annually. CureVac's vaccine is also to be filled in Heidelberg - at a Celonic plant. In addition, CureVac itself is building a large vaccine factory of its own in Tübingen, Germany, for one billion doses annually.<-------
$6.7 B marketcap and not one penny of earnings.... nor even any forecast earnings. You're smarter than this Stoney. Dude, don't fall into this sea of complacency. Yes I'm sure it will up another 8% tomorrow... and if one thinks they're quicker than average bear in the game of WS musical chairs.... buy into this BS. But until a stock can prove it WILL make money (given the benefit of the doubt on its current lack thereof).... I would not touch a stock like this with a 100 yard pole. The whole used car thing is waaaaay overplayed. Wanna know what one of the top most shorted stocks on the NAZ is... Carvana. And if any of them will survive, this one will. Not to mention CarMax has deeper pockets than any of them combined. Whatever Stoney. Stick with CureVac and Affirm... and even those two are iffy, but they'll probably be ok.
EU To Allow U.S. Travelers To Visit This Summer, If Fully Vaccinated The EU will allow Americans to visit this summer if they are fully vaccinated It is the news that many Americans have been waiting for; that they will be able to visit the EU over summer. Ursula von der Leyen, president of the European Commission, told The New York Times in Brussels on Sunday that Americans who have been fully vaccinated, will be allowed to visit European countries over the summer. It is understood, that although a date has not yet been given for when travel can begin, it will be allowed because of two reasons: firstly, the successful roll out of the vaccination program in the U.S. and secondly, because of the agreement between all 27 EU countries on the need to use vaccination certificates–France became the first EU country to trial its version on flights.
Stoney! SPAC Gummy of the Day? $SEAH $10.80 _______________ Super Group to Combine with Sports Entertainment Acquisition Corp. to Create NYSE-Listed Global Gaming Company Super Group is the holding company for leading global online sports betting and gaming businesses: Betway, a premier online sports betting brand, and Spin, a multi-brand online casino offering The group is licensed in 23 jurisdictions throughout Europe, the Americas and Africa, took in more than $42 billion in wagers in the 12 months to March 2021 and currently has over 2.5 million monthly unique active customers Targeting the fast-growing U.S. online sports betting and gaming market, Super Group has also entered into an agreement to acquire Digital Gaming Corporation (“DGC”) (subject to customary regulatory closing conditions), which will give the group access to up to an initial 10 U.S. states, complementing its global growth strategy The group ‒ which will be debt-free and have approximately $200 million in cash on its balance sheet at closing ‒ delivered $1.1 billion in net gaming revenue (NGR) and $259 million EBITDA in 2020 on a pro-forma basis and forecasts: NGR of more than $1.5 billion and EBITDA of over $350 million in 2021 NGR of more than $1.7 billion and EBITDA of over $420 million in 2022 Super Group’s management team brings decades of experience: CEO Neal Menashe, an industry pioneer, President and COO Richard Hasson and CFO Alinda van Wyk, collectively bring over 50 years of experience. Eric Grubman, former executive at the NFL, will become Chairman of Super Group and John Collins, former executive at the NHL, the NFL’s Cleveland Browns and the NFL will serve on the Super Group Board of Directors SGHC Limited (“SGHC”, “Super Group” or the “Company”) has entered into a definitive agreement with Sports Entertainment Acquisition Corp. (NYSE: SEAH) ("SEAH"), a publicly traded special purpose acquisition company, to bring its leading global online sports betting and gaming group to the U.S. public markets. The group’s successful sports betting and online gaming offerings are underpinned by its scale and leading technology, enabling fast and effective entry into new markets, while its proprietary marketing and data analytics engine empowers it to responsibly provide a unique and customized customer experience. The combination with SEAH will give Super Group access to the capital markets and a strong platform to accelerate its global growth strategy, as well as expansion into the fast-growing U.S. online sports betting and gaming market. Neal Menashe, CEO of Super Group, said: “We have established our group as a truly global, scaled and profitable digital gaming business, delivering on our vision to bring first-class entertainment to the worldwide betting and gaming community. Becoming a public company will give us the tools to continue to grow our leading product and technology offering and deliver a strengthened brand-driven marketing strategy.” “This listing will position us strongly to capitalize on the significant global growth opportunities ahead ‒ including in the U.S. market ‒ enabling us to further expand our robust, loyal and engaged customer base. In Eric and John, we have found the perfect partners with expertise across sports, entertainment and public markets to help us navigate our next phase of growth.” Eric Grubman, Chairman of the Board of Directors of SEAH, said: “Super Group is an online gaming and betting powerhouse with a track record of global growth and a strong balance sheet. Super Group’s core DNA is rooted in digital technology, which drives its unparalleled expertise in data and analytics. Neal and Super Group’s diverse and multi-talented global team have a great playbook for how to successfully launch and achieve profitable growth in new markets, and we look forward to partnering closely with them on this exciting next chapter as a public company.”
Luminar stock climbs on Airbus collab for autonomous flights Apr. 26, 2021 8:54 AM ETLuminar Technologies, Inc. (LAZR) Luminar Technologies(NASDAQ:LAZR) is collaborating with Airbus subsidiary Airbus UpNext to enhance the sensing, perception, and system-level capabilities to ultimately enablesafe autonomous flights. The tie-in is Luminar's first foray into the aviation industry. The effort is part of the new Airbus Flightlab ecosystem that launched in January. Flightlab uses flight testing as a way to prove out a variety of future technologies.
Jessica Alba’s The Hottest Ass Company sets IPO at $14-$17/share, valuing firm at up to $1.5B Actress Jessica Alba’s lifestyles brand The Honest Company Inc. (HNST) released specifics Monday for its upcoming IPO, with the firm and certain investors offering 25.8M to the public at $14 to $17 apiece. Plans call for the stock to trade on the Nasdaq under the ticker symbol “HNST.” The company plans to offer some 6.5M shares as part of the initial public offering, while certain of its pre-IPO shareholders will sell another 19.4M more. The firm is also offering underwriters the option to buy some 3.9M additional shares for overallotments. HNST wrote in a revised S-1 filing with the U.S. Securities and Exchange Commission that it expects to have some 90.5M shares outstanding following the IPO. That will value the company at about $1.3B to $1.5B on an undiluted basis, depending on where the IPO prices in its $14- to $17-a-share range.
This company is incredibly undervalued. It is the ugly stepson of the CRISPER stocks I have owned it on and off again in the past it is VERY cheap here with their program now going forward!!! Buy on any pullback-- QURE UniQure shares rise 8% as FDA lifts clinical hold on hemophilia B gene therapy program The FDA hasremoved the clinical holdon UniQure's(NASDAQ:QURE)hemophilia B gene therapy program after determining the Company satisfactorily addressed all issues identified by the Agency related to a single patient diagnosed with hepatocellular carcinoma (HCC) in the HOPE-B trial. “Our comprehensive investigation showed that AMT-061 (etranacogene dezaparvovec) is very unlikely to have contributed to the HCC in our patient. We look forward to announcing top-line 52-week data from the HOPE-B pivotal trial later this quarter,” stated Ricardo Dolmetsch, Ph.D., President of R&D. Following a surgical resection of both tumor and adjacent liver tissue, multiple analyses show that AAV vector integration in the patient’s tissue sample was extremely rare and accounted for 0.027% of the cells in the sample. The integration events were distributed randomly across the genome, and there was no evidence of clonal expansion or any dominant integration event. Additionally, whole genome sequencing confirmed that the tumor had genetic mutations that are characteristic of HCC and are independent of vector integration. Finally, gene expression analysis and adjacent tissue suggested a precancerous state in the liver that may have predisposed this patient to HCC. QURE shares rise 8.4% premarket trading at $35.00. Previously in Dec. 2020, FDA placed the hemophilia B program on clinical hold following the diagnosis of HCC in one patient in the HOPE-B trial.
Palantir Technologies: Valuing A Company Of No Profitability Apr. 25, 2021 2:40 PM ETPalantir Technologies Inc. (PLTR) Palantir presents a good opportunity to value a bubble-like stock with no meaningful company profitability. Palantir’s Government segment is a pipeline for long-term, low-risk deferred income, while the Commercial segment is like a high-margin corporate option waiting to be exercised. At this point, the Commercial segment future growth needs Microsoft, Amazon, or Google ecosystem’s investments much more than Cathie Wood’s investments. At this point, investors value Palantir's growth more than its profitability. As a result, Palantir's shares may be fairly valued between $28 and $33.